AU2001243219A1 - Methods of prevention and treatment of asthma, and allergic conditions - Google Patents

Methods of prevention and treatment of asthma, and allergic conditions

Info

Publication number
AU2001243219A1
AU2001243219A1 AU2001243219A AU4321901A AU2001243219A1 AU 2001243219 A1 AU2001243219 A1 AU 2001243219A1 AU 2001243219 A AU2001243219 A AU 2001243219A AU 4321901 A AU4321901 A AU 4321901A AU 2001243219 A1 AU2001243219 A1 AU 2001243219A1
Authority
AU
Australia
Prior art keywords
asthma
prevention
treatment
methods
allergic conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001243219A
Inventor
Simon Skurkovich
Boris Sukurkovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Biotherapy Concepts Inc
Original Assignee
Advanced Biotherapy Concepts Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biotherapy Concepts Inc filed Critical Advanced Biotherapy Concepts Inc
Publication of AU2001243219A1 publication Critical patent/AU2001243219A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001243219A 2000-02-24 2001-02-23 Methods of prevention and treatment of asthma, and allergic conditions Abandoned AU2001243219A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09511972 2000-02-24
US09/511,972 US6846486B1 (en) 2000-02-24 2000-02-24 Method of treating allergy by administering an anti-histamine antibody
PCT/US2001/005660 WO2001062287A1 (en) 2000-02-24 2001-02-23 Methods of prevention and treatment of asthma, and allergic conditions

Publications (1)

Publication Number Publication Date
AU2001243219A1 true AU2001243219A1 (en) 2001-09-03

Family

ID=24037164

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001243219A Abandoned AU2001243219A1 (en) 2000-02-24 2001-02-23 Methods of prevention and treatment of asthma, and allergic conditions

Country Status (3)

Country Link
US (4) US6846486B1 (en)
AU (1) AU2001243219A1 (en)
WO (1) WO2001062287A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277460T3 (en) 1998-12-14 2007-07-01 Genetics Institute, Llc CHAIN OF THE CYTOKIN RECEIVER.
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
DE60239522D1 (en) * 2001-01-09 2011-05-05 Baylor Res Inst Dallas METHOD FOR THE TREATMENT OF AUTOIMMUNE DISORDERS IN A PROBAND AND DIAGNOSTIC IN VITRO ASSAYS
ATE554790T1 (en) * 2001-12-07 2012-05-15 Univ Wyoming METHODS AND COMPOSITIONS FOR DIAGNOSING ASTHMA
US20050287159A1 (en) * 2002-03-25 2005-12-29 Drivas Dimitrios T Treatment methods for eotaxin mediated inflammatory conditons
ATE435239T1 (en) 2002-03-29 2009-07-15 Schering Corp HUMAN MONOCLONAL ANTIBODIES TO INTERLEUKIN-5 AND THESE COMPREHENSIVE METHODS AND COMPOSITIONS
JP2006501249A (en) * 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド vaccine
US20060147417A1 (en) * 2002-08-30 2006-07-06 Claire Ashman Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
MXPA05010222A (en) * 2003-03-24 2006-05-22 Mercia Pharma Llc Methods and compositions for treating and preventing inflammatory conditions.
US7613153B2 (en) * 2003-11-06 2009-11-03 Interdigital Technology Corporation Access points with selective communication rate and scheduling control and related methods for wireless local area networks (WLANs)
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (en) * 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
AU2005291741B2 (en) * 2004-10-07 2011-11-24 Universitat Zurich Type I interferon blocking agents for prevention and treatment of psoriasis
KR101363120B1 (en) * 2005-02-10 2014-02-13 베일러 리서치 인스티튜트 Anti-Interferon Alpha Monoclonal Antibodies and Methods for Use
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
CA2657763C (en) 2006-08-03 2016-05-31 Vaccinex Inc. Anti-il-6 monoclonal antibodies and uses thereof
SE532249C2 (en) * 2006-11-13 2009-11-24 Theravac Pharmaceuticals Ab New formulations of IL-18 for the treatment of various inflammatory diseases by vaccination
SE532250C2 (en) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab New formulations of IL-33 for the treatment of inflammatory conditions with a strong TH2 component by vaccination
ES2614284T3 (en) * 2007-11-30 2017-05-30 Glaxo Group Limited Antigen binding constructs
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009135861A2 (en) * 2008-05-07 2009-11-12 Novo Nordisk A/S Humanized antibodies against human interferon-alpha
AU2010231516A1 (en) * 2009-03-30 2011-10-27 Protab Ltd. Adenylyl Cyclase-Associated Protein (CAP1) and uses thereof as a target for immuno-modulation
WO2011035128A1 (en) * 2009-09-17 2011-03-24 Mutual Pharmaceutical Company, Inc. Method of treating asthma with antiviral agents
CN110770250A (en) 2017-04-21 2020-02-07 金德雷德生物科学股份有限公司 IL4/IL13 receptor molecules for veterinary use
KR102121122B1 (en) * 2018-11-01 2020-06-09 전북대학교산학협력단 Peptides that specifically bind histamine and their use
CN111518211B (en) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 Pharmaceutical application of human interleukin 4receptor alpha monoclonal antibody

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
ES2061416T3 (en) 1990-10-12 1997-03-01 Max Planck Gesellschaft MODIFIED RIBOZYMES.
US5510339A (en) * 1993-02-02 1996-04-23 Mayo Foundation For Medical Education And Research Method for the treatment of bronchial asthma by administration of topical anesthetics
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
CA2160583A1 (en) 1993-04-16 1994-10-27 Stanley A. Plotkin Recombinant cytomegalovirus vaccine
AU2195395A (en) 1994-03-28 1995-10-17 United Biomedical Inc. Synthetic peptide based immunogens for the treatment of allergy
US5858682A (en) 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody

Also Published As

Publication number Publication date
WO2001062287A1 (en) 2001-08-30
US20050013799A1 (en) 2005-01-20
US20050019305A1 (en) 2005-01-27
US20050013800A1 (en) 2005-01-20
US6846486B1 (en) 2005-01-25

Similar Documents

Publication Publication Date Title
AU2001243219A1 (en) Methods of prevention and treatment of asthma, and allergic conditions
AU2002323210A1 (en) Bio-synthetic photostimulators and methods of use
WO2001078781A8 (en) Methods for prevention and treatment of gastrointestinal disorders
AU2002314466A1 (en) Withasol and methods of use
AU2002361563A1 (en) Anti-tombstoning structures and methods of manufacture
AU2002366338A1 (en) Catheter having improved curve retention and method of manufacture
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AUPR839001A0 (en) Dosage form, device and methods of treatment
AU2002356868A1 (en) Methods for the prevention or treatment of bacterial and fungal infections
AU2002335085A1 (en) Angiopoietins and methods of use thereof
AU2003209851A1 (en) Method of treatment and/or prophylaxis
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU6887101A (en) Copolymers and methods of treating prion-related diseases
AU2001247471A1 (en) Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
AU2002366028A1 (en) Use of fk506 and analogues for treating allergic diseases
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002219473A1 (en) Treatment of asthma and other lung conditions
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
AU2001253560A1 (en) Methods of treatment
AU2002246307A1 (en) Polyherbal composition for the treatment of bronchial asthma and the process
AUPR626001A0 (en) A method of treatment and/or prophylaxis